Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.


Navigating the Anticommons for Pharmaceutical Patents
Richard A. Epstein, Bruce N. Kuhlik, John. M. Olin Law and Economics Working Paper, 3-1-04

The current U.S. pharmaceutical patent protection regime strikes the right balance between financial incentives to supply innovative new products and generic drug competition.

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000